- The trend backdrop is active with a 4-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
HIKAL
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Hikal Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
227.1 INR
2.6%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 14.8% above the Trend Line and sits at 54.9% of its 52-week range. The latest completed week returned 2.6%, after a -7.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100.
Setup score
50
out of 100
Latest Close
227.1 INR
7 Aug 2026
1W Return
2.6%
latest completed week
4W Return
-7.2%
short-term follow-through
12W Return
12.7%
quarterly tape
Trend Breadth
7.7%
4 of 52 weeks active
Volume Ratio
2.2x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
2.6%
Latest completed week; four-week move -7.2%.
Indicator stack
18/72
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
27 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 14.8% above the Trend Line and sits at 54.9% of its 52-week range. The latest completed week returned 2.6%, after a -7.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 2.2x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.4212-week average 0.24
12-week confirmation
Trend active4/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership6/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.42Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -7.2% over four weeks, 12.7% over 12 weeks, and -21.5% over one year. The current trend has remained active for 4 consecutive weeks.
Performance by holding period
Active trend streak4 weeks
Active weeks in one year4
Trend breadth7.7%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.26Latest activity-pressure read.
Pressure change-4.4%Four-week change in activity pressure.
Leadership5.69Latest relative-leadership reading.
RS change-52.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength34/100Blend of value, momentum, and quality. Underlying universe rank 67; rank 1 is best.
Value61/100Relative valuation strength. Underlying universe rank 40; rank 1 is best.
Quality36/100Profitability and accounting quality. Underlying universe rank 65; rank 1 is best.
Momentum20/100Medium-term price momentum. Underlying universe rank 81; rank 1 is best.
Growth19/100Revenue and earnings growth. Underlying universe rank 82; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework4/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 1.7x Market value relative to trailing revenue.
- EV / EBITDA
- 23.5x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 4.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 55.1% Gross profit retained from each unit of revenue.
- Operating margin
- 3.3% Operating profit retained from revenue.
- Free-cash-flow margin
- 9.1% Free cash flow generated from revenue.
- Return on invested capital
- 2.3% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -8.0% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 7.5% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 5/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.4% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.4% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 4.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 27 relevant articles.
5 positive · 18 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-22.6%Distance below the 52-week high.
13-week volatility5.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+18.9%Week of 13 Feb.
Worst week-7.7%Week of 6 Mar.
Latest week+2.6%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains5
Flat weeks0
Modest losses4
Sharp losses9
Recent vol5.6%13-week weekly-return volatility.
Base vol6.0%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -4.1%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank89 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank77 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape49/100
Trend, activity pressure, participation, and risk combine to a 49/100 tape read.
Indicator analysis55/100Latest 12-week confirmation: trend 4/12, activity pressure 12/12, relative leadership 6/12.
Activity pressure 0.42; No reversal markers Factors37/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 36; Small Cap Core rank 40 SVQF4/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1507.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 27 relevant articles.
Hikal Q1 Results: Earnings Call Scheduled for August 6 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 227.1 INR | 2.6% | 197.9 INR | 293.9 INR | 1.26 | 5.69 | 5.2M | On |
| 31 Jul 2026 | 221.3 INR | 1.8% | 197.5 INR | 294.3 INR | 1.37 | 3.17 | 807.6K | On |
| 24 Jul 2026 | 217.4 INR | -5.0% | 197.7 INR | 294.8 INR | 1.43 | 3.12 | 1.7M | On |
| 17 Jul 2026 | 228.8 INR | -6.5% | 198.2 INR | 295.2 INR | 1.46 | 5.07 | 2.9M | On |
| 10 Jul 2026 | 244.8 INR | 10.2% | 198.5 INR | 295.6 INR | 1.31 | 11.94 | 13.8M | Off |
| 3 Jul 2026 | 222.1 INR | 3.3% | 198.8 INR | 296.0 INR | 0.98 | 0.59 | 122.6K | Off |
| 26 Jun 2026 | 214.9 INR | 5.0% | 199.5 INR | 296.5 INR | 0.79 | -2.69 | 0 | Off |
| 19 Jun 2026 | 204.8 INR | 11.3% | 199.7 INR | 297.1 INR | 0.78 | -8.11 | 723.6K | Off |
| 12 Jun 2026 | 184.0 INR | -3.0% | 200.4 INR | 297.8 INR | 0.77 | -17.06 | 147.5K | Off |
| 5 Jun 2026 | 189.6 INR | -2.9% | 201.9 INR | 298.6 INR | 0.93 | -14.87 | 163.4K | Off |
| 29 May 2026 | 195.3 INR | -4.9% | 203.3 INR | 299.4 INR | 1.11 | -14.16 | 3.2M | Off |
| 22 May 2026 | 205.3 INR | 1.9% | 204.8 INR | 300.2 INR | 1.10 | -11.57 | 880.5K | Off |
| 15 May 2026 | 201.5 INR | -4.4% | 206.0 INR | 300.6 INR | 1.02 | -14.24 | 1.2M | Off |
| 8 May 2026 | 210.8 INR | 11.4% | 207.3 INR | 301.3 INR | 0.91 | -13.42 | 2.8M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.